The article is published as part of an exclusive content-sharing agreement with neo-trans.blog .

Following government approval of a new therapy to treat a rare genetic skin disorder, Abeona Therapeutics Inc. revealed through public records that it plans another expansion of its footprint next to its Midtown Cleveland headquarters.

The 10-year-old, publicly traded (Nasdaq: ABEO) therapeutics venture, based in Building Three of the Midtown Tech Park , 6555 Carnegie Ave., revealed that it plans to invest $2.85 million to expand into a neighboring building of the Midtown Tech Park. It is not known how many new jobs will come with this expansion, but is likely fewer than two dozen.

In a permit application submitted last week to the Cleveland Building Department, the company plans to

See Full Page